VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering May 10, 2016 07:36PM
VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors Mar 30, 2016 08:05AM
VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression Mar 22, 2016 08:05AM
VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder Jul 1, 2015 09:30AM